​

Mirum Pharmaceuticals (MIRM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

MIRM Stock Forecast

Mirum Pharmaceuticals (MIRM) stock forecast, based on 18 Wall Street analysts, predicts a 12-month average price target of $116.70, with a high of $140.00 and a low of $95.00. This represents a 27.55% increase from the last price of $91.49.

- $30 $60 $90 $120 $150 High: $140 Avg: $116.7 Low: $95 Last Closed Price: $91.49

MIRM Stock Rating

Mirum Pharmaceuticals stock's rating consensus is Buy, based on 18 Wall Street analysts. The breakdown includes 1 Strong Buy (5.56%), 17 Buy (94.44%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 18 0 17 1 Strong Sell Sell Hold Buy Strong Buy

MIRM Price Target Upside V Benchmarks

TypeNameUpside
StockMirum Pharmaceuticals27.55%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-521
Avg Price Target-$126.40$105.19
Last Closing Price$91.49$91.49$91.49
Upside/Downside-38.16%14.97%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2638---11
Mar, 2637---10
Feb, 2628---10
Jan, 2628---10
Dec, 2528---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 04, 2026Gavin Clark-GartnerEvercore ISI$126.00$89.3740.99%37.72%
Feb 26, 2026Mani ForooharLeerink Partners$118.00$92.7827.18%28.98%
Feb 26, 2026Joe KimRBC Capital$128.00$94.1435.97%39.91%
Feb 17, 2026RBC Capital$130.00$102.8326.42%42.09%
Jan 26, 2026H.C. Wainwright$130.00$94.2937.87%42.09%
Jan 20, 2026Evercore ISI$101.00$91.1310.83%10.39%
Jan 13, 2026H.C. Wainwright$102.00$89.5013.97%11.49%
Jan 12, 2026Robert W. Baird$95.00$89.506.15%3.84%
Dec 19, 2025UBS$140.00$70.2899.20%53.02%
Dec 11, 2025Steven SeedhouseRaymond James$110.00$65.1268.92%20.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 27, 2026Cowen & Co.BuyBuyhold
Feb 26, 2026Leerink PartnersOutperformOutperformhold
Feb 26, 2026Evercore ISIOutperformOutperformhold
Feb 26, 2026RBC CapitalOutperformOutperformhold
Feb 17, 2026RBC CapitalOutperforminitialise
Jan 20, 2026Evercore ISIOutperformOutperformhold
Jan 13, 2026H.C. WainwrightBuyBuyhold
Jan 12, 2026Cowen & Co.BuyBuyhold
Dec 19, 2025CitigroupOutperformOutperformhold
Dec 19, 2025CitigroupMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

$-10 $-6 $-2 $2 $6 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.77$-4.01$-4.00$-1.85$-0.47---
Avg Forecast$-4.48$-4.03$-3.37$-1.62$-0.62$0.62$2.92$4.97
High Forecast$-4.10$-3.79$-3.07$-0.43$0.83$4.99$6.98$5.97
Low Forecast$-5.21$-4.65$-3.62$-1.98$-1.28$-1.13$0.49$4.54
Surprise %-38.17%-0.50%18.69%14.20%-24.19%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$19.14M$77.06M$186.37M$336.89M$521.31M---
Avg Forecast$78.42M$76.00M$184.64M$333.95M$422.98M$521.39M$718.97M$919.96M
High Forecast$88.19M$84.88M$186.67M$336.76M$483.39M$521.39M$830.15M$1.06B
Low Forecast$73.23M$72.47M$179.31M$332.51M$396.78M$521.39M$670.45M$857.89M
Surprise %-75.60%1.40%0.94%0.88%23.25%---

Net Income Forecast

$-250M $-140M $-30M $80M $190M $300M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-83.99M$-135.66M$-163.41M$-87.94M$-23.36M---
Avg Forecast$-183.22M$-164.93M$-136.73M$-49.23M$-36.95M$44.32M$162.92M$203.34M
High Forecast$-167.46M$-154.97M$-125.39M$-17.48M$33.78M$203.99M$285.38M$244.21M
Low Forecast$-212.90M$-189.98M$-148.08M$-80.98M$-52.35M$-46.16M$20.03M$185.50M
Surprise %-54.16%-17.74%19.51%78.64%-36.77%---

MIRM Forecast FAQ

Is Mirum Pharmaceuticals stock a buy?

Mirum Pharmaceuticals stock has a consensus rating of Buy, based on 18 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 17 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Mirum Pharmaceuticals is a favorable investment for most analysts.

What is Mirum Pharmaceuticals's price target?

Mirum Pharmaceuticals's price target, set by 18 Wall Street analysts, averages $116.7 over the next 12 months. The price target range spans from $95 at the low end to $140 at the high end, suggesting a potential 27.55% change from the previous closing price of $91.49.

How does Mirum Pharmaceuticals stock forecast compare to its benchmarks?

Mirum Pharmaceuticals's stock forecast shows a 27.55% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Mirum Pharmaceuticals over the past three months?

  • April 2026: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 20.00% Strong Buy, 80.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Mirum Pharmaceuticals’s EPS forecast?

Mirum Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $0.62, marking a -231.91% decrease from the reported $-0.47 in 2025. Estimates for the following years are $2.92 in 2027, and $4.97 in 2028.

What is Mirum Pharmaceuticals’s revenue forecast?

Mirum Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $521.39M, reflecting a 0.01% increase from the reported $521.31M in 2025. The forecast for 2027 is $718.97M, and $919.96M for 2028.

What is Mirum Pharmaceuticals’s net income forecast?

Mirum Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $44.32M, representing a -289.68% decrease from the reported $-23.363M in 2025. Projections indicate $162.92M in 2027, and $203.34M in 2028.